DBV Technologies S.A. is looking to raise approximately $150 million via the sale of company shares.
The French biotechnology company is looking to sell 2,784,030 American depositary shares at $21.26 each in the U.S., Canada and certain non-European countries, and another 2,135,737 ordinary shares in Europe for €34.71 apiece.
Morgan Stanley and Goldman Sachs are acting as joint lead book-running managers for the global offering. Barclays and Deutsche Bank Securities are also serving as book-running managers.
Bryan Garnier & Co. is acting as a co-manager for the global offering.
The offering's underwriters will have an option to buy up to an additional 529,162 ordinary shares.
The company will use the proceeds to fund, among other things, the development and commercialization of its allergy treatment Viaskin Peanut.